On Feb. 1, 2021, Dynavax Technologies announced Valneva had informed it that the UK Government exercised its option to order an additional 40 million doses of Valneva’s SARS-CoV-2 adjuvanted vaccine candidate, VLA2001. This option exercise triggered the reservation of additional quantities of Dynavax’s advanced adjuvant CpG 1018 to support production of 40 million doses of Valneva’s SARS-CoV-2 adjuvanted vaccine candidate, VLA2001.

In connection with its contract with the UK Government, Valneva had reserved for delivery in 2021 CpG 1018 in quantities sufficient to support production of 100 million doses of VLA2001.